Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 8/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.38 |
| ▸ | FEN1 | P39748 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | PDE5A | O76074 | 3/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24286250 | 0.80 | ABL1 (0.42) | TGFBR1ABL1LRRK2 | |
| SCHEMBL24286257 | 0.78 | TGFBR1 (0.37) | TGFBR1ABL1LRRK2 | |
| SCHEMBL24286673 | 0.78 | ABL1 (0.45) | ABL1LRRK2 | |
| SCHEMBL24286244 | 0.78 | ABL1 (0.45) | ABL1LRRK2 | |
| SCHEMBL24286132 | 0.78 | ABL1 (0.45) | ABL1LRRK2 | |
| SCHEMBL24286618 | 0.74 | LRRK2 (0.40) | TGFBR1ABL1LRRK2 | |
| SCHEMBL24285971 | 0.71 | LRRK2 (0.42) | TGFBR1ABL1LRRK2 | |
| SCHEMBL24286579 | 0.70 | ABL1 (0.47) | TGFBR1MAPK14ABL1LRRK2 | |
| SCHEMBL24286572 | 0.70 | ACVR1 (0.43) | TGFBR1MAPK1RAB9A | |
| SCHEMBL9870817 | 0.67 | TP53 (0.70) | TP53MAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11744824-B2 | 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds | 1ST Biotherapeutics, Inc. (KR) | 2023-09-05 | — | — | US | disclosed |
| US-20220087985-A1 | 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS | 1ST Biotherapeutics, Inc. (KR) | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11744824-B2 | 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds | NLRP3, NLRP1, KCNJ2 | TGFBR1 3044/4885ALOX5AP 1565/4885FEN1 4830/4885 |
| US-20220087985-A1 | 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS | NLRP3, NLRP1, KCNJ2 | TGFBR1 3044/4885ALOX5AP 1565/4885FEN1 4830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.